Browsing by Author "Sadat, Jasmin"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- A cross-linguistic perspective to the study of dysarthria in Parkinson’s diseasePublication . Pinto, Serge; Chan, Angel; Guimarães, Isabel; Rothe-Neves, Rui; Sadat, JasminCross-linguistic studies aim at determining the similarities and differences in speech production by uncovering linguistic adaptations to specific constraints and environments. In the field of motor speech disorders, such a crosslanguage approach could be of great interest to understand not only the deficits of speech production that are induced by the pathology, but also the difficulties that are induced by the linguistic constraints specific to the patients’ language. From a more clinical point of view, cross-linguistic studies should specifically focus on the relationship between speech disorders and speech intelligibility. The aim of this opinion article is to identify the currently scarce theoretical and clinical avenues for cross-linguistic studies of dysarthria in Parkinson’s disease, and to establish guidelines that would lead future research in this direction. In turn, the practical and behavioral management of dysarthria in Parkinson’s disease has so far only focused on the ‘universal’ dimensions of speech production and feedback (e.g., treatment of loudness and dysprosody). Such approaches could benefit immensely from proper recommendations that would be more ‘language-driven’ and individually adapted to the patients’ language environment. An additional factor to consider for a better understanding and treatment of dysarthria in PD is the role of adjustment and cultural identity.
- Dysarthria in individuals with Parkinson’s disease: a protocol for a binational, cross-sectional, case-controlled study in rrench and european portuguese (FraLusoPark)Publication . Pinto, Serge; Cardoso, Rita; Sadat, Jasmin; Guimarães, Isabel; Mercier, Céline; Santos, Helena; Atkinson-Clement, Cyril; Carvalho, Joana; Welby, Pauline; Oliveira, Pedro; D’Imperio, Mariapaola; Frota, Sónia; Letanneux, Alban; Vigario, Marina; Cruz, Marisa; Martins, Isabel Pavão; Viallet, François; Ferreira, JoaquimIntroduction: Individuals with Parkinson’s disease (PD) have to deal with several aspects of voice and speech decline and thus alteration of communication ability during the course of the disease. Among these communication impairments, 3 major challenges include: (1) dysarthria, consisting of orofacial motor dysfunction and dysprosody, which is linked to the neurodegenerative processes; (2) effects of the pharmacological treatment, which vary according to the disease stage; and (3) particular speech modifications that may be language-specific, that is, dependent on the language spoken by the patients. The main objective of the FraLusoPark project is to provide a thorough evaluation of changes in PD speech as a result of pharmacological treatment and disease duration in 2 different languages (French vs European Portuguese). Methods and analysis: Individuals with PD are enrolled in the study in France (N=60) and Portugal (N=60). Their global motor disability and orofacial motor functions is assessed with specific clinical rating scales, without (OFF) and with (ON) pharmacological treatment. 2 groups of 60 healthy age-matched volunteers provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks are recorded to obtain acoustic and perceptual measures. Patient-reported outcome measures are used to assess the psychosocial impact of dysarthria on quality of life. Ethics and dissemination: The study has been approved by the local responsible committees on human experimentation and is conducted in accordance with the ethical standards. A valuable largescale database of speech recordings and metadata from patients with PD in France and Portugal will be constructed. Results will be disseminated in several articles in peer-reviewed journals and in conference presentations. Recommendations on how to assess speech and voice disorders in individuals with PD to monitor the progression and management of symptoms will be provided.